U.S. starts review for national Medicare coverage policy for Biogen’s Aduhelm

Article content

The U.S. government on Monday started a review process for national Medicare coverage of Biogen Inc’s Alzheimer’s drug, Aduhelm, that was recently approved by the country’s health regulator.

The Centers for Medicare & Medicaid Services expects to give a proposed decision within 6 months and a final decision within 9 months. (https://go.cms.gov/3hzMa6H) (Reporting by Trisha Roy in Bengaluru; Editing by Shounak Dasgupta)

Source link


How Can Young Entrepreneurs Better Manage Their Company

It's not easy being an entrepreneur. You're constantly taking risks, stretching your limits, and trying to keep afloat in a sea of uncertainty. But...

Videocon Group: NCLT doubts Videocon’s sale remained confidential

(This story originally appeared in on Jun 16, 2021)MUMBAI: In its order approving the resolution plan submitted by for the Videocon...